<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024295</url>
  </required_header>
  <id_info>
    <org_study_id>XMX-AH-001</org_study_id>
    <nct_id>NCT02024295</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis</brief_title>
  <official_title>Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Hisun Pharmaceutical Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Hisun Pharmaceutical Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the efficacy and safety S-adenosyl-l-methionine in alcoholic hepatitis with
      cholestasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomize first time for core treatment stage for 6 weeks, then randomized second time for
      extend treatment for 42 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate of serum total bilirubin</measure>
    <time_frame>6 weeks</time_frame>
    <description>response rate means percentage of subjects whose serum total bilirubin values declined from baseline over 30%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>level of serum direct bilirubin</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of serum bile acids</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of glutamic pyruvic transaminase</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of glutamic oxaloacetic transaminase</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of alkaline phosphatase</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of gamma-glutamyl transpeptidase</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level of hyaluronic acid</measure>
    <time_frame>6 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Liver biopsy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Liver biopsy is not demanded</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Hepatitis, Alcoholic</condition>
  <arm_group>
    <arm_group_label>Ademethionine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polyene Phosphatidyl choline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ademethionine</intervention_name>
    <description>ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.</description>
    <arm_group_label>Ademethionine</arm_group_label>
    <other_name>ademethionine for 6 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyene Phosphatidyl choline</intervention_name>
    <description>Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.</description>
    <arm_group_label>Polyene Phosphatidyl choline</arm_group_label>
    <other_name>Polyene Phosphatidyl choline for 6 weeks</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ademethionine</intervention_name>
    <description>after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks</description>
    <arm_group_label>Ademethionine</arm_group_label>
    <arm_group_label>Polyene Phosphatidyl choline</arm_group_label>
    <other_name>stage 2, ademethionine for 42 weeks.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index range 19-30kg/m2

          -  Alcohol Drinking history more than 5 years, for male ≥ 40g/ day, for female ≥ 20g/
             day;

          -  STB from 2 to 10X ULN;

          -  ALP&gt;1.5X ULN or GGT&gt;3X ULN

        Exclusion Criteria: any one of below,

          -  active virus hepatitis, or anti-HIV(+)

          -  exclude other hepatic disease: non-alcoholic fatty liver, drug-induced liver injury,
             autoimmune hepatitis( AMA/ANA&gt;1:100), Wilson disease, hemochromatosis or other hepatic
             disease; obstructive cholestasis

          -  other non-hepatic diseases caused jaundice

          -  primary hepatic carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Ditan Hospital affiliated ffiated to Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Cheng</last_name>
    <phone>8610-84322000</phone>
    <email>jun.cheng.ditan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Ditan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Cheng</last_name>
      <phone>8610-84322566</phone>
      <email>jun.cheng.ditan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jun Cheng</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Cheng</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>May 28, 2014</last_update_submitted>
  <last_update_submitted_qc>May 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Cholestasis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choline</mesh_term>
    <mesh_term>Polyene phosphatidylcholine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

